Aug 17 (Reuters) - Trillium Therapeutics Inc TR.TO
* Trillium Therapeutics receives FDA clearance to proceed with TTI-621 in clinical trial targeting solid tumors and mycosis fungoides Source text for Eikon: ID:nNRA2fj4ue Further company coverage: TR.TO